Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Noosa News23 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News21 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News22 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
General19 hours agoDairy farmers devastated by floods across parts of New South Wales